Peel Hunt reiterated their hold rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a research report sent to investors on Thursday morning.

Other analysts also recently issued research reports about the stock. Numis Securities Ltd reaffirmed an add rating and issued a GBX 1,560 ($20.52) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 17th. Morgan Stanley downgraded shares of Hikma Pharmaceuticals Plc to an equal weight rating and lowered their target price for the company from GBX 2,050 ($26.96) to GBX 1,600 ($21.04) in a report on Wednesday, August 2nd. Jefferies Group LLC lowered their target price on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.28) to GBX 1,045 ($13.74) and set a hold rating on the stock in a report on Monday, August 21st. Stifel Nicolaus downgraded shares of Hikma Pharmaceuticals Plc to a hold rating and lowered their target price for the company from GBX 2,300 ($30.25) to GBX 1,320 ($17.36) in a report on Tuesday, August 29th. Finally, J P Morgan Chase & Co lowered their target price on shares of Hikma Pharmaceuticals Plc from GBX 1,500 ($19.73) to GBX 1,250 ($16.44) and set a neutral rating on the stock in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold and an average price target of GBX 1,321.91 ($17.39).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down GBX 17.04 ($0.22) during trading hours on Thursday, hitting GBX 981.46 ($12.91). 2,310,000 shares of the stock traded hands, compared to its average volume of 823,245. Hikma Pharmaceuticals Plc has a 1-year low of GBX 934 ($12.28) and a 1-year high of GBX 2,346 ($30.86).

TRADEMARK VIOLATION NOTICE: “Hikma Pharmaceuticals Plc (HIK) Earns “Hold” Rating from Peel Hunt” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/hikma-pharmaceuticals-plc-hik-earns-hold-rating-from-peel-hunt/1698580.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.